Neuronetics Announces Elevation of Sara Grubbs to SVP, Chief Revenue Officer
16 févr. 2023 16h12 HE
|
Neuronetics
MALVERN, Pa., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Announces Updated Medicare Policy Expanding Access to NeuroStar TMS Therapy through Nurse Practitioners
10 févr. 2023 16h15 HE
|
Neuronetics
MALVERN, Pa., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Announces Data Confirming Efficacy in Treating Anxious Depression with NeuroStar® Advanced Therapy for Mental Health
17 janv. 2023 08h32 HE
|
Neuronetics
MALVERN, Pa., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Announced as a Winner by 2022 Merit Awards for HealthCare in the Patient Care Category
05 déc. 2022 08h32 HE
|
Neuronetics
MALVERN, Pa., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Announces NeuroStar® Advanced Therapy for Mental Health System Innovations
14 nov. 2022 08h33 HE
|
Neuronetics
MALVERN, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Announced as Winner by 2022 Merit Awards for Technology
31 oct. 2022 08h31 HE
|
Neuronetics
MALVERN, Pa., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Announces Updated TMS Coverage Policies That Will Expand Patient Access to NeuroStar TMS Therapy for Mental Health
25 oct. 2022 10h31 HE
|
Neuronetics
MALVERN, Pa., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Launches Innovations To NeuroStar® Advanced Therapy’s Proprietary TrakStar® Platform
26 sept. 2022 08h31 HE
|
Neuronetics
MALVERN, Pa., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that...
Neuronetics, Inc. Announces Grand Opening of NeuroStar® University with Ribbon-Cutting Ceremony
13 sept. 2022 08h33 HE
|
Neuronetics
MALVERN, Pa., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Announces 510(k) Clearance of D-Tect™ MT Accessory for NeuroStar® Advanced Therapy for Mental Health
29 août 2022 08h30 HE
|
Neuronetics
MALVERN, Pa., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...